Antiatherogenic Properties of tert-Butylhydroquinone
叔丁基氢醌的抗动脉粥样硬化特性
基本信息
- 批准号:6786512
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-15 至 2007-02-28
- 项目状态:已结题
- 来源:
- 关键词:acute phase proteinantiatherogenic agentaorta disorderatherosclerosiscardiovascular disorder chemotherapycardiovascular disorder riskcardiovascular pharmacologycholesterolcomputer program /softwaredietary lipiddisease /disorder modeldrug design /synthesis /productiondrug screening /evaluationgenetically modified animalshydroquinoneslaboratory mouselipid metabolismnonhuman therapy evaluationprotein localizationprotein metabolismstatistics /biometrytriglycerides
项目摘要
DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and triglycerides in a rat model. TBHQ is phenolic antioxidant commonly used as a food preservative. A patent, "Method for Reducing Blood Cholesterol and/or Blood Triglycerides," was subsequently obtained. The long-term objective of this research proposal is to determine the antiatherogenic potential of TBHQ and advance its commercial development. Our specific aims are to test the efficacy of TBHQ in: (1) reducing aortic atherosclerosis; (2) lowering plasma lipid levels; (3) promoting a less atherogenic lipoprotein profile and; (4) reducing plasma levels of C-reactive protein (CRP). Elevated levels of CRP are a risk factor for cardiovascular disease. In our phase I experiments, we will use the apoE knockout (apoE-/-) mouse model since it has been extensively used to study the antiatherogenic potential of other phenolic antioxidants. Our preliminary market analysis suggests that TBHQ could have a potential market of $100 million per year as a lipid-lowering agent. Commercial development should be accelerated since NIH has already conducted extensive toxicological studies with TBHQ.
描述(申请人提供):动脉粥样硬化是大多数心血管疾病的根本原因,相当多的证据支持高胆固醇血症是这种疾病的危险因素。在初步工作中,我们发现叔丁基对苯二酚(TBHQ)在低于批准的人类使用剂量时,可以有效地降低大鼠模型中总胆固醇和甘油三酯的水平。TBHQ是一种酚类抗氧化剂,通常用作食品防腐剂。随后获得了专利“降低血液胆固醇和/或甘油三酯的方法”。这项研究计划的长期目标是确定TBHQ的抗动脉粥样硬化潜力,并推动其商业化发展。我们的具体目标是测试TBHQ在以下方面的有效性:(1)减少主动脉粥样硬化;(2)降低血脂水平;(3)促进较少的动脉粥样硬化形成脂蛋白;(4)降低血浆C-反应蛋白(CRP)水平。C反应蛋白水平升高是心血管疾病的危险因素。在我们的第一阶段实验中,我们将使用apoE基因敲除(apoE-/-)小鼠模型,因为它已被广泛用于研究其他酚类抗氧化剂的抗动脉粥样硬化潜力。我们的初步市场分析表明,TBHQ作为一种降脂剂,每年可能有1亿美元的潜在市场。应该加快商业开发,因为NIH已经与TBHQ进行了广泛的毒理学研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William L Stone其他文献
Gamma (γ) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (γ) expression in SW 480 human colon cancer cell lines
- DOI:
10.1186/1471-2407-3-25 - 发表时间:
2003-10-01 - 期刊:
- 影响因子:3.400
- 作者:
Sharon E Campbell;William L Stone;Sarah G Whaley;Min Qui;Koyamangalath Krishnan - 通讯作者:
Koyamangalath Krishnan
912 STUDIES RELATED TO THE CRISIS EPISODES IN SICKLE CELL PATIENTS
- DOI:
10.1203/00006450-198504000-00942 - 发表时间:
1985-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Saburo Hara;Parimal K Adhikary;Robert E Hardy;Chandradhar Dwivedi;William L Stone;Cynthia Weaver;Carolyn Taylor;Dharmdeo M Singh;Festus O Adebonojo - 通讯作者:
Festus O Adebonojo
THE INFLUENCE OF SURFACTANT ON WATER SOLUBLE ANTIOXIDANTS IN BRONCHOALVEOLAR LAVAGE FROM PREMATURE INFANTS. 1164
- DOI:
10.1203/00006450-199604001-01186 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Des Bharti;William L Stone;Qinglin Tan;Thomas T.S Huang - 通讯作者:
Thomas T.S Huang
William L Stone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William L Stone', 18)}}的其他基金
ANTIOXIDANTS AND THE KINETICS OF LIPOPROTEIN OXIDATION
抗氧化剂和脂蛋白氧化动力学
- 批准号:
2221583 - 财政年份:1992
- 资助金额:
$ 10万 - 项目类别: